Story
Twist Bioscience Stock Gains After Eli Lilly AI Drug Discovery Deal
Summary
Twist Bioscience (TWST) shares climbed after the company announced an agreement to provide antibody data services for Eli Lilly's AI-powered drug discovery platform, TuneLab.
Shares of Twist Bioscience Corp. (NASDAQ:TWST) climbed on Wednesday following the announcement of a collaboration with Eli Lilly and Company (NYSE:LLY). The agreement will see Twist provide antibody characterization data services for TuneLab, Lilly's artificial intelligence and machine learning (AI/ML) drug discovery platform.
The Agreement in Detail
Under the terms of the deal, Twist will support TuneLab by generating high-quality experimental data. According to the announcement, TuneLab users will be able to order antibody services directly from Twist using preferred protocols to create "wet lab" data for training and refining AI models, including the AbLab antibody developability prediction model.
This partnership aims to bridge the gap between experimental research and computational drug discovery. By providing a streamlined way to generate reliable data, the collaboration is designed to help researchers more rapidly identify and advance promising antibody drug candidates.
Market Impact and Rationale
AdFollowing the news, shares in Twist Bioscience rose by 3%. The deal underscores the growing importance of high-quality, large-scale datasets for training effective AI in the pharmaceutical industry.
"The quality of an AI model’s output depends on the quality of the data used to train it," said Emily M. Leproust, CEO and co-founder of Twist Bioscience, in a statement. She added that Twist's high-throughput capabilities can supply the consistent data needed for these models. The arrangement also provides TuneLab users with preferred pricing to more efficiently select antibody sequences and contribute data back for federated training.
Context on Lilly's AI Platform
Lilly TuneLab was established to accelerate biotech innovation by allowing participating companies to access AI/ML drug discovery models trained on Eli Lilly's extensive proprietary research data. It is a component of Lilly Catalyze360, a broader initiative that also includes venture capital, lab space, and R&D support to foster new developments in the biotech sector.
Read next
More on Stocks
ExxonMobil in Advanced Talks for Venezuela Return, Eyeing Former Orinoco Project
The U.S. oil major is reportedly negotiating a return to the Petromonagas heavy oil project, a significant reversal nearly two decades after its assets were nationalized by the Venezuelan government.
US House Passes Bill Targeting Data Center Power Grid Costs
The U.S. House of Representatives has advanced the Ratepayer Protection Act, the first legislation of its kind aimed at making large power users like data centers bear the costs of new electricity infrastructure.
New Zealand's Q2 GDP Growth Exceeds Forecasts but Remains Tepid at 0.2%
New Zealand's economy grew 0.2% in the second quarter, topping analyst and central bank forecasts, according to official data. However, the pace of expansion remains slow amid persistent economic headwinds and recent interest rate hikes.
Snap Partners With Salesforce, Nvidia to Target Enterprise Market With AR Glasses
Snap Inc. has announced strategic partnerships with Salesforce, Nvidia, and Amazon Web Services to integrate enterprise-grade AI and software tools into its Specs augmented-reality glasses, signaling a major push into the corporate market.